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Abstract 
 
Diabetes mellitus (DM) is a major global health problem, 
currently affecting about 460 million people while another 
billion have prediabetes, all costing the governments of the 
world over $1 trillion USAD to diagnose and treat diabetic 
patients, so that they can enjoy a better quality of life. DM 
induces hyperglycemia (HG), which in turn plays a 
significant role in the development of diabetic 
cardiomyopathy (DCM), which is responsible for over 80% 
of diabetic mortality. The exact mechanisms underlying 
DCM remain incompletely clear, although several 
pathological mechanisms responsible for DCM have been 
proposed in the literature. One such mechanism is oxidative 
stress (OS), which is widely considered as one of the major 
causes for the pathogenesis of the disease. There is a 
growing scientific and public interest in connecting 
oxidative stress with a variety of pathological conditions, 
including DM as well as other human diseases. HG-induced 
oxidative stress is a major risk factor for the development 
of micro-vascular pathogenesis in the diabetic myocardium, 
resulting in myocardial cell death, hypertrophy, fibrosis, 
abnormalities of calcium homeostasis and endothelial 
dysfunction. The aim of this review is to highlight the role 
of oxidative stress in the development of DCM. 
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Introduction 
 
Diabetes mellitus (DM) has been recognized as a 
major cause for the development of diabetic 
cardiomyopathy (DCM) for decades, resulting in 
morbidity and mortality diabetic patients [1]. There is 
a large body of evidence suggesting that the body of a 
diabetic patient is prone to significant changes at the 
cellular, subcellular and molecular levels, causing 
structural and functional abnormalities in the 
myocardium and vasculature, leading to DCM [2-7]. 
In the development of DC, hyperglycemia (HG) 
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results in tissue damage by both acute reversible 
changes in cellular metabolism and irreversible 
changes in macromolecules [8]. HG can cause long-
term damage to multiple organs, resulting in sever 
complication [9, 10]. The micro-vasculature is a key 
target of HG–induced damages to small blood vessels 
initiating systematic complications and end organ 
failures [11, 12]. One major contributor to HG-
induced diabetic abnormalities is increased oxidative 
stress (OS) [13]. The possible biochemical 
mechanism is increased OS [14]. Moreover, OS has 
been linked to the onset of DM and its complication 
[15, 16]. Endothelial cells dysfunction (ECD), 
mitochondrial dysfunction (MD), inflammation and 
abnormal vascular remodeling are associated with 
myocardial apoptosis, fibrosis and hypertrophy seen 
in DC [17]. ECD is a result of the activation of 
endothelial cells from a quiescent phenotype to 
vasoconstrictive, pro-inflammatory and pro-apoptotic 
states [18]. During DM, endothelial cells are exposed 
to high fluctuating blood glucose concentrations; this 
exposure is a known factor for ECD [19]. 
Furthermore, HG can stimulate the production of 
reactive oxygen species (ROS) as well as the 
production of toxic by-products of glycolysis, 
primarily methylglyoxal (MGO), leading to the 
formation of advanced glycation end-products 
(AGEs) [20]. In DM, the production of MGO is 
accelerated while its detoxification is slowed, leading 
to MG accumulation [21]. Elevated MGO 
concentrations have been shown to promote 
inflammatory responses that activate endothelial cells, 
subsequently leading to ECD and vascular damage 
[22]. New insights into the mechanisms that increase 
oxidative stress in DM might lead to novel treatment 
strategies [23]. This review attempts to address the 
role of oxidative stress in the development of DCM.  
 
 
Oxidative Stress 
 
Oxidative stress (OS) is characterized by the 
imbalance between free radicals and antioxidants. 
This imbalance could be as a result of increased free 
radical production and/or decreased antioxidants 
capacity [24, 25]. The imbalance between free 
radicals and antioxidant systems gives rise to free 
radical-mediated damage, mainly reactive oxygen 
species (ROS) [26, 27]. ROS can cause damage to the 
mitochondria together with poly (ADP-ribose) 
polymerase-1 (PARP) activation, leading to the 
inhibition of the cytosolic enzyme glyceraldehyde-
3phosphate dehydrogenase (GAPDH). This inhibition 
initiates a series of cellular processes by activation 
pathways that lead to HG-associated cellular damage 
[28]. Inhibition of GAPDH diverts glucose from 
glycolytic pathways into alternative biochemical 
pathways, including the polyol pathway and AGE 
formation [29]. Under normal physiological 
conditions, cellular glucose is predominantly 
phosphorylated into glucose 6-phosphate by 
hexokinase, thereby entering the glycolytic pathway. 
Only trace amounts of non-phosphorylated glucose 
(about 3%) enter the polyol pathway [30]. However, 
during HG, there is increased flux through the polyol 
pathway, accounting for greater than 30% of glucose 
metabolism [31]. The polyol pathway converts 
hexose sugars such as glucose into sugar alcohols 
(polyols). For example, glucose can be converted into 
sorbitol via the action of the enzyme aldose reductase. 
Aldose reductase is the rate-limiting enzyme for this 
pathway [32]. Increased aldose reductase activity and 
accumulation of sorbitol have been found in diabetic 
animal models. As sorbitol does not easily move 
across cell membranes, this results in an increase in 
cellular osmolality, ultimately leading to cell damage. 
Sorbitol may also glycate nitrogen molecule on 
proteins, such as collagen, producing AGE products 
[32]. Increased polyol flux is associated with reduced 
concentrations of intracellular glutathione and an 
increase in cardiac cell apoptosis [33].  
 
 
Cardiovascular Complications and AGEs 
 
Advanced glycation end-products (AGEs), also 
known as glycotoxins, may play an important role in 
the pathobiology of DCM and heart failure [9]. AGEs 
are either proteins or lipids that become glycated after 
exposure to sugars. They are prevalent in the diabetic 
vasculature and contribute to the development of 
atherosclerosis. They have been shown to be 
increased in plasma by HG [9]. Currently, it is 
believed that AGEs are linked to many diseases [34]. 
In fact, AGE in the myocardium is increased in both 
T1DM and T2DM, and positive correlations of serum 
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concentration of AGEs with ventricular isovolumetric 
relaxation time, arterial stiffness, and carotid intimal 
thickness have been shown in DM [9]. Consequently, 
it is important to understand the pathophysiology 
processes of AGEs.  
 
 
Formation of AGEs 
 
AGEs are produced in our body and can also be 
consumed through foods. They are formed through a 
process called glycation. In 1912, the French 
Scientist, Louis-Camille Maillard investigated the 
non-enzymatic reaction between the free amino 
groups of proteins and carbonyl groups of reducing 
sugars or other carbonyl compounds [35]. This 
Maillard reaction can be divided into two parts. The 
first part/half proceeds until Amadori rearrangement; 
the second half involves AGE formation through 
reactions such as oxidation, dehydration, and 
condensation. 
During the early stage, either glucose or other 
reducing sugars such as fructose react with a free 
amino group of biological amines to form an unstable 
compound (Figure 1). This glycation reaction results 
in the formation of the Schiff base, which undergoes a 
rearrangement to a more stable product known as 
Amadori product [36]. Then, the Amadori product 
degrades to a variety of reactive dicarbonyl 
compounds such as Methylglyoxal (MGO) via 
dehydration, oxidation and other chemical reactions. 
In the late stage of glycation, irreversible compounds 
called AGEs are formed through oxidation, 
dehydration and cyclization reactions. The AGEs are 
yellow-brown, fluorescent and insoluble adducts that 
accumulate on long-lived proteins, thus inducing their 
physiological dysfunction [37].  
 
 
Figure 1. Flow diagram showing steps of advanced glycation end-products (AGEs) generation, leading to structural and 
functional changes at the cellular and subcellular level in the myocardium. 
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Receptors for Advanced Glycation  
End Products 
 
Formation of AGEs leads to the activation of 
different signaling pathways mediated by a series of 
cell surface receptors. The most studied AGE-receptor 
is the multi-ligand receptor for advanced glycation 
end products (RAGE) [38]. RAGE is a 
transmembrane protein on the cellular surface that 
recognizes tridimensional molecules, instead of amino 
acid sequences, making this molecule capable of 
interacting with diverse ligands. RAGE represents an 
important factor in innate immunity against 
pathogens, but it also interacts with endogenous 
ligands, resulting in chronic inflammation. RAGE 
signaling has been implicated in multiple human 
illnesses, including diabetes, atherosclerosis, arthritis, 
Alzheimer's disease, and aging- associated diseases. 
Ligation of RAGE on the cellular surface triggers a 
series of cellular signaling events, including the 
activation and translocation to the nucleus of 
transcription factor NF-B, leading to inflammation 
and oxidative stress [39]. 
 
 
Accumulation of the AGEs 
 
Since the discovery of the Millard reaction, 
significant efforts have recently been made in 
proteomics research, which is a comprehensive study 
of expressed proteins in the human body. Many 
studies subsequently led to the identification of 
diseases, which cannot be cured, simply by studying 
gene or protein expression. The Maillard reaction has 
also recently attracted new attention for its role as a 
post-translational modification, promoted by an 
abnormality in the metabolism of sugars and lipids. 
AGEs can change the physicochemical properties of 
proteins, such as net negative charge degeneration and 
polymerization [40]. Normally, there is a balance 
between oxidants and antioxidant defense. During 
DM, the equilibrium of pro-oxidants and antioxidants 
shifts to the former, leading to a marked rise in 
reactive oxygen species (ROS). Elevated 
concentrations of oxidants promote the oxidation of 
lipids and glucose, resulting in the accelerated 
formation of AGEs. Alterations of extracellular 
proteins, such as collagen and elastin, as well as the 
activation of different signaling pathways after 
intracellular uptake, are the consequences of 
increasing AGE concentrations. Consequently, 
increasing concentrations of AGES support the 
formation of reactive oxygen and nitrogen species, 
which in turn induce further formation of AGEs [38]. 
 
 
Pathological Impact of AGEs 
 
Formation of AGE can contribute to tissue 
damage. Its accumulation in collagen was associated 
with reduced collagen turnover, indicating the 
possibility that cross-linking of collagen makes 
collagen resistant to hydrolytic turnover. Such AGE-
mediated cross-linking of collagen is thought to be 
responsible for increased stiffness of arteries and the 
myocardium [9]. Also, AGEs can cause inactivation 
of the sarcoplasmic-endoplasmic ATPASE pump 
(SERCA) and the Ryanodine receptor (RYR2) 
calcium release channel. Interestingly, DM has been 
closely associated with accumulation of AGEs in the 
myocardium and also with a positive correlation of 
serum concentration of AGEs with ventricular 
isovolumetric relaxation time, arterial stiffness, and 
carotid intimal thickness [9]. 
 
 
Production of ROS 
 
HG can stimulate the overproduction of ROS and 
reactive carbonyl species (RCS). ROS and RCS are 
significant contributors to structural and functional 
abnormalities in the diabetic heart [41]. Diabetic 
mitochondria produce more ROS than normal 
mitochondria [42]. Mitochondria are the major source 
of ROS production. Cellular sources of ROS 
generation within the heart include cardiac myocytes, 
endothelial cells and neutrophils. Furthermore, it has 
been reported that the activation of the renin-
angiotensin system (RAS) in DM is associated with 
increased oxidative damage, fibrosis and cell 
apoptosis [43]. Inhibition of the RAS was shown to 
reduce ROS production in streptozotocin-induced 
diabetic rats, similar to the effect observed with 
antioxidant treatment [44]. Angiotensin (Ang-II) 
given exogenously to rodents has been shown to 
cause cellular changes within the myocardium, 
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leading to hypertrophy and fibrosis [45]. ROS induces 
cellular damage through many mechanisms, including 
oxidation, interference with nitric oxide and 
modulation of detrimental intracellular signaling 
pathways. Thus, increased ROS concentration leads to 
cardiac dysfunction by direct damage to proteins and 
DNA and apoptosis [46]. RCS are diverse in chemical 
structures and are derived from multiple sources, 
including auto-oxidation of glucose and lipids, triose 
pathway fluxes and enzymes such as methylglyoxal 
synthase. RCS also have unique characteristics 
compared to ROS in that their half-lives are longer 
(minutes vs. millisecond), and they are uncharged 
molecules, allowing them to migrate distances far 
from their site of production [47]. 
 
 
MGO 
 
MGO is a di-carbonyl aldehyde mainly formed as 
byproduct of glycolysis [48]. By its nature, MGO 
efficiently reacts with other molecules in the 
organism, causing cell and tissue dysfunction [49]. 
Recent studies have demonstrated that increased 
methylglyoxal-derived AGE concentrations in 
diabetic patients are associated with diabetic 
complications, such as DCM [50]. MGO 
concentrations in healthy humans have been estimated 
to be about 50–150 nM in plasma and 1–4 µM in 
tissues [22]. When the concentration of MGO exceeds 
these values, di-carbonyl stress occurs as a 
consequence of the imbalance between the 
generation/exposure and MGO metabolism [51]. 
Under physiological conditions, >99% of MGO are 
detoxified by the glyoxalase system [52], with minor 
metabolism by aldoketo-reductases (AKRs) and 
aldehyde dehydrogenases (ADHs), which convert 
MGO to hydroxyacetone and pyruvate, respectively 
[53]. 
 
 
Glyoxalase System 
 
The glyoxalase system consists of glyoxalase 1 
(Glo1), glyoxalase 2 (Glo2) and a catalytic amount of 
glutathione [54]. Abnormal cellular accumulation of 
the MGO occurs upon exposure to high glucose 
concentrations, oxidative stress, inflammation, and 
cell aging. It is associated with increased MGO-
adduct content of proteins susceptible to di-carbonyl 
modification, collectively defined as di-carbonyl 
proteome [51], and with DNA instability and 
mutations [55]. An adequate balance between MGO 
concentrations and Glo1 activity is necessary to 
ensure detoxification of MGO from different sources 
and cell survival. In TIDM, MGO production 
increases; the increase in blood MGO may be 
responsible in part for the dysregulation of ECs in the 
vasculature of end organs. However, to the best of our 
knowledge, the concentration of MGO in blood of 
patients and animals with T1DM is typically ≤2 μM 
[56], which is signiﬁcantly lower than the 
concentrations (well over 10 μM) needed to potentiate 
mitochondrial ROS production, and which perturbs 
intracellular Ca2+ homeostasis and impairs endothelial 
function in vitro [57]. Moreover, erythrocytes contain 
high concentrations of the rate-determining 
methylglyoxal-degrading enzyme glyoxalase-I (Glo-
I), and its cofactor reduced GSH [58] that rapidly 
degrades this diffusible electrophile and prevents its 
accumulation. This discrepancy led to search for non-
blood sources of methylglyoxal that could be 
responsible for dysregulation of ECs in T1MD. 
Vascular adhesion protein-1 (VAP-1) is best known 
as an inﬂammation-induced adhesin that is up-
regulated in high endothelial venules to aid in the 
extra- vasation of leukocytes from the blood into 
tissues [59]. VAP-1 is also expressed on the 
membrane of smooth muscle cells (SMCs) [60]. In 
DM, endothelial cells (ECs) are directly exposed to 
HG, which is a known contributing factor to the loss 
of endothelial function (Figure 2). The ECs play an 
important role in cardiomyocyte viability and function 
and in myocardial homeostasis ECs death can lead to 
repeated episodes of ischemia and myocardial 
infarction, the death of cardiomyocytes, and the 
development of ventricular dysfunction, leading to 
heart failure [61]. Although there is now considerable 
scientific evidence that MGO engenders the 
development of vascular complications, further 
experimental research is needed to pinpoint the 
underlying causal mechanisms. 
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Figure 2. Flow diagram showing changes occurring during diabetes and how increased oxidative stress can lead to structural 
and functional changes at the cellular and subcellular level in the myocardium. 
 
Conclusion 
 
The flow diagram in Figure 2 is a summary of the 
relationship between diabetes-induced hyperglycemia 
and the development of diabetic cardiomyopathy, 
employing different signaling pathways to generate 
oxidative stress and subsequently cardiac dysfunction. 
There is considerable evidence that induction of 
oxidative stress is a key process in the onset of 
diabetic complications. The precise mechanisms by 
which oxidative stress may accelerate the 
development of complications in diabetes are only 
partly known. MGO accumulation has harmful effects 
on vascular function, by inducing insulin-resistance, 
hypertension, atherosclerosis, neurodegenerative 
disease and diabetic microvascular complications. 
The complete mechanism responsible for 
development of DCM is not fully clear, but some 
previous studies have identified pathways that may 
involve the down-expression of GLO-1 and over-
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expression of VAP-1. Therefore, protecting the 
vasculature from MGO may be a target for future 
studies and therapy to postpone and reduce the 
development of heart failure in DM. 
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